Navigation Links
Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)
Date:4/20/2011

f women living with PMO."

The 12-month Phase 2 study is a multi-center, international, randomized, placebo-controlled, parallel-group study designed to evaluate the effect of AMG 785/CDP7851 compared to placebo in women with low BMD, and to characterize the safety and tolerability of AMG 785/CDP7851.  Approximately 400 postmenopausal women with low BMD (T-scores between -2.0 and -3.5) are enrolled in the study. Treatment arms included dosing at 70, 140 and 210 mg subcutaneously once a month, and 140 and 210 mg every three months, against matched placebo for all treatment groups.

Detailed results will be submitted for presentation at a future medical congress.

AMG 785/CDP7851 is a humanized monoclonal antibody that binds to and inhibits sclerostin, a protein secreted by bone cells that inhibits bone formation. By binding to and blocking sclerostin, AMG 785/CDP7851 is designed to allow the body to add more bone to the skeleton. Amgen and UCB have collaborated for the development of AMG 785/CDP7851 for the treatment of bone-related conditions, including PMO and fracture healing.

About Amgen

Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com.

About UCB

UCB, Brussels, Belgium (www.ucb.co
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amgen’s First Quarter 2011 Revenue Increased 3 Percent to $3.7 Billion
2. Amgen to Webcast 2011 Business Review Meeting on April 21
3. Amgen Announces Webcast of 2011 First Quarter Financial Results
4. Amgen Establishes Commercial Operations in Brazil
5. Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe
6. Amgen Donates $1 Million to Help Japanese Disaster Victims
7. Amgen Completes Acquisition of BioVex
8. NBPTS and Amgen Foundation Join to Bolster Science Education
9. Amgen to Present at the Citi 2011 Global Healthcare Conference
10. CURE Magazine Teams Up With Amgen Oncology and Breakaway from Cancer® to Launch 2011 Extraordinary Healer Award for Oncology Nursing
11. Boehringer Ingelheim to Purchase Amgens Fremont (USA) Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), a ... operations in China and ... release financial results for the second quarter of 2014 after ... 2014 (which will be Thursday morning, August 14, 2014 Shanghai ... relations section of the Company,s website at http://www.wuxiapptec.com ...
(Date:7/22/2014)... , July 22, 2014  Pressure ... "Company") and Parabase Genomics ("Parabase"), (together "the ... a strategic research and development agreement (the ... PBI will develop a front-end, sample preparation ... and newborn confirmatory testing process. The sample ...
(Date:7/22/2014)... PORT WASHINGTON, New York , ... Neue Partnerschaft für umfassenden ... gefährlichen Medikamenteneinwirkungen in Österreich    ... führender Anbieter von geschlossenen Transfersystemen (Closed System ... Medikus , einen Vertriebshändler und ...
Breaking Medicine Technology:WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 3Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 4Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2
... Nov. 1, 2011 Lexicon Pharmaceuticals, Inc. ... on discovering and developing breakthrough treatments for human disease, ... results for the three and nine months ended September ... studies of LX4211 and LX1032 have provided further validation ...
... Corporation (NASDAQ: VOLC ), a leading developer and ... to enhance the treatment of coronary and peripheral artery disease, ... increased 18 percent versus the third quarter of 2010. ... revenues of $85.8 million versus revenues of $72.9 million in ...
Cached Medicine Technology:Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results 2Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results 3Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results 4Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results 5Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results 6Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results 7Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results 8Volcano Reports 18 Percent Increase in Total Third Quarter Revenues 2Volcano Reports 18 Percent Increase in Total Third Quarter Revenues 3Volcano Reports 18 Percent Increase in Total Third Quarter Revenues 4Volcano Reports 18 Percent Increase in Total Third Quarter Revenues 5Volcano Reports 18 Percent Increase in Total Third Quarter Revenues 6
(Date:7/22/2014)... Get Real Health announced today ... (IDF) to provide their patient community with a ... to electronically track their symptoms, medications and other health-related ... also allow those patients and families who want ... data shared with the U.S. Immunodeficiency Network (USIDNET) ...
(Date:7/22/2014)... July 22, 2014 Atreo Services will ... service and support programs and accessories in booth #1423 ... Conference & Technical Exhibition in Chicago, Ill., Aug. 3-6. ... pneumatic tube system carriers as well as its selection ... brand-name hospital tube systems. In addition, representatives will ...
(Date:7/22/2014)... Altec Products, Inc. , a leader ... their Gold Sponsorship of Sage Summit 2014 ... and Casino in Las Vegas, Nevada. The largest educational ... in taking advantage of the many opportunities to network ... and educate themselves on the latest enterprise resource planning ...
(Date:7/22/2014)... Dr. Allen Kamrava, colorectal surgeon in Beverly ... new website dedicated to the diagnosis and treatment of ... DrKamrava.com . , “With this new website, I ... trustworthy source for various colorectal conditions ,” says ... colon cancer, hernias, or more, patients will find that ...
(Date:7/22/2014)... FL (PRWEB) July 22, 2014 ... opened registration for multiple upcoming real estate investing workshops ... potentially life-changing events are designed to introduce people to ... in the Canadian market. , A total of 9 ... a period of three weeks. The goal is to ...
Breaking Medicine News(10 mins):Health News:Get Real Health to Partner with Immune Deficiency Foundation 2Health News:Get Real Health to Partner with Immune Deficiency Foundation 3Health News:Atreo Services to Introduce Pneumatic Tube System Solutions at ASHE Annual Conference 2Health News:Altec Announces Gold Sponsorship of Sage Summit 2014 2Health News:Altec Announces Gold Sponsorship of Sage Summit 2014 3Health News:Los Angeles Doctor Launches Brand New Website for Colorectal Surgery and Treatment 2Health News:Los Angeles Doctor Launches Brand New Website for Colorectal Surgery and Treatment 3Health News:Brick Buy Brick Announces Multiple 1-Day Real Estate Workshops Coming to Toronto 2
... Calif., April 1, 2008 MAQUET Cardiovascular,LLC ... infringement complaints,in the United States International Trade ... District of Northern California against Terumo Corporation,and ... that,Terumo infringes two MAQUET U.S. patents through ...
... have found that community health center-trained family physicians were ... non-community health center-trained counterparts (64 percent versus 37 percent), ... of Family Medicine. The news comes on the heels ... Program that there is an increased interest in family ...
... College of Cardiology during,ceremonies at the 57th Annual ... CHICAGO, April 1, 2008 Robert O. Bonow, ... Northwestern Memorial Hospital, and Goldberg Distinguished Professor of,Northwestern ... the,American College of Cardiology (ACC) as Master of ...
... 1, 2008 Faced with shrinking,staffs and less ... time serving the hospital marketplace. As their time,to ... for the,pharma industry are turning to other decision-makers ... formularies, according to research from benchmarking,leader Best Practices, ...
... for Heightened Autism Awareness among Hispanic Community as Fewer ... Receiving Diagnosis and Support, ... its services for individuals living with autism, among the,vast array of ... ones., Over the last 20 years, Easter Seals has seen ...
... Co-Chairs and Leading Grassroots Autism Association Push,for Services ... The United,Nations has designated April 2 as World ... Autism Society of America, the World Autism,Organization and ... Research and Education (C.A.R.E.), Rep. Chris Smith and ...
Cached Medicine News:Health News:MAQUET Cardiovascular Announces Patent Infringement Complaints Against Terumo 2Health News:Want docs to treat the underserved? Make sure they train at community health centers 2Health News:Robert Bonow, MD Honored for Outstanding Service by the American College of Cardiology 2Health News:Robert Bonow, MD Honored for Outstanding Service by the American College of Cardiology 3Health News:Effectively Influencing the Hospital Marketplace to Win a Place on Formularies 2Health News:Easter Seals Notes April's Autism Awareness Month to Highlight Services Available to Families Living With Autism 2Health News:Easter Seals Notes April's Autism Awareness Month to Highlight Services Available to Families Living With Autism 3Health News:Reps. Smith and Doyle, Autism Society of America Push Landmark Legislation on World Autism Awareness Day 2Health News:Reps. Smith and Doyle, Autism Society of America Push Landmark Legislation on World Autism Awareness Day 3
Form should always follow function. Thats why EagleVision created the FlexPlug, the only tapered shaft punctum plug with contouring traction ribs. Designed to provide the ultimate in flexibility, fix...
The latest wave in punctum plugs! Unique design featureing reservoir indentations to reduce foreign body sensation. Elast™ - a proprietary formulated, hight performance Liquid Silicon Rubber ...
... Attain Prevail's steerable tip, along with various ... obtain the curve you need, when you ... visualization of the cardiac venous anatomy, adjust ... - Adjust curve and reach by ...
... Attain™ Deflectable Catheter - designed to be ... single catheter. Steerablility - Create a variety ... a single, steerable guide catheter. Lock the ... to address each patient's unique anatomy during ...
Medicine Products: